Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Factor IX Inhibitors and Anaphylaxis in Hemophilia B

Warrier, Indira, Ewenstein, Bruce M., Koerper, Marion A., Shapiro, Amy, Key, Nigel, DiMichele, Donna, Miller, Robert T., Pasi, John, Rivard, Georges E., Sommer, Steve S., Katz, Jacob, Bergmann, Frauke, Ljung, Rolf, Petrini, Pia, Lusher, Jeanne M. · 1997 · Journal of Pediatric Hematology/Oncology

Abstract

PURPOSE: We present clinical and laboratory data on 18 children from 12 hemophilia treatment centers in the United States, Canada, and Europe with the purpose of disseminating information regarding a recently recognized, potentially life-threatening complication of treatment in very young children with hemophilia B. PATIENTS AND METHODS: Twelve hemophilia centers from the United States, Canada, and Europe provided clinical information and laboratory data concerning 18 children who had severe allergic reactions to infused factor (F) IX in close association with the development of an inhibitor to FIX. Laboratory testing for establishment of the diagnosis of hemophilia B and inhibitor to FIX was done locally at the centers treating these patients. FIX gene analysis was performed at one of six molecular genetics institutes. RESULTS: All 18 children had severe hemophilia B, and in each an inhibitor antibody to FIX developed. The median age at the time of anaphylaxis (or anaphylactoid reaction) was 16 months, and the median number of exposure days to FIX was 11. The FIX inhibitor was detected almost simultaneously with the first occurrence of anaphylaxis in 12 of 18 patients. Maximum inhibitor titers were 4.5-600 Bethesda units (BU), with a median titer of 48 BU. FIX gene analysis, performed in 17 of 18 patients, demonstrated complete deletion of the FIX gene in 10 and major derangements in seven. Immune tolerance induction (ITI) regimens have been attempted in 12 patients, with generally poor responses. Two of the 12 experienced nephrotic syndrome while on ITI. Recombinant FVIIa has been successfully used to treat bleeding episodes in 11 of these children. CONCLUSION: Physicians treating young children with hemophilia B should be aware of the potentially life-threatening complication of anaphylaxis. Children with complete gene deletions or major derangements of the FIX gene appear to be at greater risk. Those identified by genotype as being at greater risk may need to receive their first 10-20 treatments in a medical facility equipped for handling such emergencies. Recombinant FVIIa, although not licensed for use in the United States, appears to be the most suitable treatment option for bleeding episodes in such patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00043426-199701000-00003

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 183

Metadata

Authors
Warrier, I., Ewenstein, B. M., Koerper, M. A., Shapiro, A., Key, N., DiMichele, D., Miller, R. T., Pasi, J., Rivard, G. E., Sommer, S. S., Katz, J., Bergmann, F., Ljung, R., Petrini, P., & Lusher, J. M.
Venue
Journal of Pediatric Hematology/Oncology
Published
1997-01
Volume
19
Issue
1
Pages
23-27
ISSN
0192-8562 (ISSN-L)
OpenAlex
W1984096039
Cited by
183
References
1
FWCI
4.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factor IX Inhibitors and Anaphylaxis in Hemophilia B. https://app.cochat.ai/papers/10.1097/00043426-199701000-00003
The paper
Warrier, I., Ewenstein, B. M., Koerper, M. A., Shapiro, A., Key, N., DiMichele, D., Miller, R. T., Pasi, J., Rivard, G. E., Sommer, S. S., Katz, J., Bergmann, F., Ljung, R., Petrini, P., & Lusher, J. M. (1997). Factor IX Inhibitors and Anaphylaxis in Hemophilia B. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/00043426-199701000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.